D-0161-2023 Class III Terminated
FDA drug recall D-0161-2023 was initiated by Lannett Company Inc. on Nov 9, 2022 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specifications The recall status is terminated (terminated Jun 8, 2023). Affected quantity: 20,040 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 25, 2023
- Initiation Date
- Nov 9, 2022
- Termination Date
- Jun 8, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 20,040 bottles
Product description
Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, [100 or 1000 ] Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC 100 Count bottle: 0527-1632-01; NDC 1,000 bottle: 0527-1632-10
Reason for recall
Failed Impurity/Degradation Specifications
Distribution pattern
Nationwide USA
Code information
Lots: 21000279A (exp 01/2023), 20256320A (12/2022)
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0161-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026